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Both genetic and environmental interactions aﬀect systemic lupus erythematosus (SLE) development and pathogenesis. One
known genetic factor associated with lupus is a haplotype of the interferon regulatory factor 5 (IRF5) gene. Analysis of global
gene expression microarray data using gene set enrichment analysis identiﬁed multiple interferon- and inﬂammation-related gene
sets signiﬁcantly overrepresented in cells with the risk haplotype. Pathway analysis using expressed genes from the signiﬁcant gene
sets impacted by the IRF5 risk haplotype conﬁrmed signiﬁcant correlation with the interferon pathway, Toll-like receptor pathway,
and the B-cell receptor pathway. SLE patients with the IRF5 risk haplotype have a heightened interferon signature, even in an
unstimulated state (P = 0.011), while patients with the IRF5 protective haplotype have a B cell interferon signature similar to that
of controls. These results identify multiple genes in functionally signiﬁcant pathways which are aﬀected by IRF5 genotype. They
also establish the IRF5 risk haplotype as a key determinant of not only the interferon response, but also other B-cell pathways
involved in SLE.
1.Introduction
Systemic lupus erythematosus is a complex disease with
multifactorial etiology and pathogenesis. Studies in identical
twins indicate that concordance for lupus is approximately
40%, indicating a strong but not exclusive genetic compo-
nent[1,2].Recentgeneticanalyseshaveidentiﬁedmorethan
thirty candidate genes that are associated with lupus risk [3–
18]. IRF5 was found to be associated with lupus by multiple
independent groups in a variety of populations [10, 13–15,
19, 20]. IRF5 risk haplotypes may function at the crossroads
of environmental risk, such as virus infection, and cellular
immune responses. At least three polymorphisms of IRF5
havebeenidentiﬁedthatcontributeindependentlytotherisk
for lupus, which together constitute the lupus risk haplotype
[10, 21]. Although the majority of the polymorphisms that
havebeenassociatedwithlupusareinnontranslatedregions,
they may aﬀect several facets of IRF5 activity, including
splicing, RNA stability, transcription factor binding, and
apoptosis [9, 10, 15, 21, 22].
IRF5 is important in the production of and response
to interferon alpha (IFNα), which is heightened in lupus.
IFNα is produced by dendritic cells, macrophages, B cells,
and other cell types, primarily in response to virus infection
[23, 24]. Dendritic cells have been shown to produce IFNα
in response to incubation with immune complex-containing2 Journal of Biomedicine and Biotechnology
sera from SLE patients [25], especially patients that have the
risk haplotype for IRF5 [19]. Additionally, serum interferon
levels, as well as the interferon response signature, are
increased in patients with the risk haplotype [19, 26]. IRF5
is an especially interesting candidate for a genetic risk factor
in lupus because it acts in pathways that control many of
the cellular and immune responses to environmental factors,
such as infection, which may contribute to lupus.
One putative environmental agent that is strongly associ-
atedwithriskforlupusisEpstein-Barrvirus(EBV)infection.
Lupus has been associated with prior EBV infection in
both pediatric and adult populations [27–33]. EBV expresses
antigens that are immunologically cross-reactive with sig-
niﬁcant lupus autoantigens such as Sm and nRNP [34–
39]. However, since over 95% of adults are infected with
EBV, determining why EBV could contribute to lupus in
certain individuals but not others has proven challenging.
The identiﬁcation of IRF5 and other genetic risk factors
for lupus open the possibility that the lupus-associated
genetic polymorphisms in one or more of these genes works
in concert with environmental factors culminating in the
increased observed risk for developing lupus. Previous work
has shown that pediatric lupus patients have broadened,
more cross-reactive humoral immune responses to EBV than
controls [40]. EBV is also not as well controlled in lupus
patients as it is in controls, with increased viral load and
alteredT-cellresponses[41,42].Diﬀerencesinviralinfection
or the response to viral infection conferred by genetic factors
such as IRF5 polymorphisms may in part explain these
observations.
Since B cells are the primary host cell for EBV infection,
we used B cells and EBV interactions as a model to study the
impact of IRF5 genotype on downstream B-cell responses.
For this study, we examined diﬀerences in B-cell gene
expression between na¨ ıve B cells from individuals with the
IRF5 risk haplotype and those with the protective or neutral
haplotypes at both basal levels and after exposure to EBV.
Na¨ ıve B cells were chosen because they are the cell type
in which EBV establishes latent infection [43]. We found
multiplenetworksofgenesthatwereenrichedfordiﬀerential
expression, as well as individual gene expression diﬀerences.
Most importantly, we identiﬁed diﬀerent expression patterns
of interferon response genes in lupus patients based on the
IRF5 risk haplotype. Understanding these diﬀerences will aid
in determining mechanisms through which the genetic risk
conferred by the IRF5 risk haplotype is manifested.
2.MaterialsandMethods
2.1. Study Participants. Genotypes were previously collected
on samples obtained from the Oklahoma Rheumatic Disease
ResourceCoresCenter(ORDRCC)attheOklahomaMedical
Research Foundation. Previously enrolled subjects were
contacted for study participation based upon their IRF5
risk and protective haplotypes using genotypes at single
nucleotide polymorphisms rs2004640 and rs10954213. Five
IRF5 high-risk (3 controls, 2 patients) and ﬁve IRF5 nonrisk
(2 controls, 3 patients) sex- and race- matched individuals
were recruited. The study was approved by the institutional
review board at OMRF and OUHSC, and informed consent
was obtained from all subjects in the study.
2.2. B-Cell Stimulation. Peripheral blood mononuclear cells
were separated by density gradient centrifugation from the
peripheral blood of volunteers. Na¨ ıve B cells were isolated
usingtheMACSNa¨ ıveBCellIsolationKitII(MiltenyiBiotec
Inc). Untouched na¨ ıve B cells were incubated at a 1:1 (v/v)
ratio with either virus-free media or infectious EBV for 16
hours. Virus preparations were in the form of B95-8 cell
culture supernatant. The same preparation of supernatant
was used for all assays.
2.3.GeneExpressionProﬁling. TotalcellularmRNAwaspuri-
ﬁed from lysates of infected and mock-infected cells using
the Ambion RNaqueous-Micro Kit (Applied Biosystems,
Austin, TX, USA) according to the manufacturer’s protocol
and quantiﬁed using a NanoDrop spectrophotometer (Nan-
oDrop Technologies, Inc.). cRNA ampliﬁcation and labeling
with biotin were performed using the Illumina TotalPrep
RNA ampliﬁcation kit protocol (Ambion, Austin, TX, USA)
on an aliquot of 200ng of total RNA. Whole genome expres-
sion analysis was performed using the Illumina HumanRef-8
v.3 gene expression chip (24,526 transcripts) following the
Illumina Whole-Genome Expression Protocol.
2.4. Statistical and Pathway Analysis. The microarray data
were analyzed using gene set enrichment analysis, and
pathway analysis to investigate changes in gene networks.
These analyses were followed by comparison of individual
gene expression diﬀerences inside these networks. Raw
expression data was ﬁrst normalized using the MDAT tool-
box [44]. Gene Set Enrichment Analysis software (Molecular
Signatures Database) was used to determine whether an a
priori functionally deﬁned set of genes showed statistically
signiﬁcant, concordant diﬀerences between two phenotypes
(IRF5 risk and nonrisk haplotypes) [45, 46]. Signiﬁcant gene
sets were identiﬁed by an enrichment score, which reﬂects
the degree to which a gene set is overrepresented at the top
or bottom of a ranked list of genes, and a false discovery
rate (FDR) of <25%. We focused our subsequent pathway
analysis on the subset of enriched genes (n = 368) from the
statistically signiﬁcant gene sets.
Pathway analyses were generated through the use
of Ingenuity Pathways Analysis (Ingenuity Systems,
http://www.ingenuity.com/). A data set containing gene
identiﬁers and corresponding expression values was
uploaded into in the application. Each gene identiﬁer was
mapped to its corresponding gene object in the Ingenuity
Pathways Knowledge Base. The expression values entered
were the normalized log (intensity) values of IRF5 nonrisk
and risk haplotype individuals, respectively.
Canonical pathways analysis identiﬁed the pathways
from the Ingenuity Pathways Analysis library of canonical
pathways that were most signiﬁcant to the data set. The
signiﬁcance of the association between the data set and
the canonical pathway was measured in two ways: (1) aJournal of Biomedicine and Biotechnology 3
ratio of the number of genes from the data set that map
to the pathway divided by the total number of genes that
map to the canonical pathway; (2) Fisher’s exact test was
used to calculate a P value determining the probability
that the association between the genes in the dataset and
the canonical pathway is explained by chance alone. All
associations are supported by at least one reference from the
literature, from a textbook, or from canonical information
stored in the Ingenuity Pathways Knowledge Base. Human
and mouse orthologs of a gene are stored as separate
objects in the Ingenuity Pathways Knowledge Base, but are
represented as a single node in the network. Heat maps
were created with previously mentioned expression values in
Spotﬁre software.
3. Results
3.1. Enrichment of Lupus-Related Gene Sets by IRF5 Risk Hap-
lotype. Using existing genotyping data for single-nucleotide
polymorphism rs2004640 (T: risk, G:p r o t e c t i v e )a n d
rs10954213 (A: risk, G:p r o t e c t i v e )[ 10, 11, 20, 21, 47] the
frequencyoftherisk,protective,andneutralIRF5haplotypes
were examined in 1,390 SLE patients and 2,039 controls
enrolledina largecohort ofEuropeanAmerican female(EA)
SLE patients from the Lupus Family Registry and Repository
(LFRR: http://lupus.omrf.org/). A signiﬁcant enrichment
for the risk and risk-neutral haplotypes was found in
lupus patients (P<0.0001), as expected (Table 1). Using
these results, ﬁve individuals with the risk or risk-neutral
haplotypes and ﬁve with the protective or protective-neutral
haplotypes were recruited from the local SLE collections
through the ORDRCC for further study. These included
two SLE patients and three controls in the risk groups, and
three SLE patients and two controls with protective and
protective-neutral haplotypes. The risk group was enriched
for controls so that the eﬀects of the IRF5 haplotypes could
be better studied in the absence of potential confounding
genetic inﬂuences or factors related to lupus.
In all, 368 genes were found to be signiﬁcantly (P<
0.05) diﬀerentially expressed between the risk and the
nonrisk individuals. Gene set enrichment analysis was used
to look for gene pathways overrepresented when comparing
expression data from the risk haplotype and the protective
haplotype phenotypic groups in the case or control groups
separately. This analysis examines 6,769 ap r i o r ideﬁned
functional gene sets [46, 48]. In the unaﬀected controls
with the risk haplotype, nine gene sets were enriched
with a false discovery rate (FDR) <25% (Table 2), and
19 were enriched with a nominal P value <0.01, but an
FDR >25% (Supplemental Table 2 which available online at
doi:10.1155/2011/594056).Inthelupuspatientswiththerisk
haplotype ﬁve gene sets were enriched with an FDR <25%.
However, four of these were diﬀerent versions of interferon-
alpha gene sets. The ﬁfth was the lupus-related interferon
response signature (Table 2) .S e v e ng e n es e t sw e r ee n r i c h e d
with a nominal P value <0.01 but a FDR >25% in the SLE
risk haplotype cells, including the Toll-like receptor (TLR)
gene set (Supplemental Table 1).
Fewer gene sets were as highly enriched in the protective
haplotype cells. No gene sets were signiﬁcantly enriched at
an FDR level <25% in either the unaﬀected controls or the
lupus patients with the protective haplotype. However, 39
gene sets were enriched at P<0.01 in the SLE patients with
the protective haplotype, and 35 gene sets were enriched at
P<0.01 level in the controls with the protective haplotype
(Supplemental Tables 3 and 4).
3.2. Identiﬁcation of Lupus-Related Pathways Diﬀerentially
Aﬀected by IRF5 Haplotype. Genes from the enriched gene
sets described above which also demonstrated diﬀerences
in expression in the previous analysis were included in a
globalpathwayanalysisusingtheIngenuityPathwayAnalysis
system. This analysis uses the curated Ingenuity Knowledge
Base to associate sets of genes and expression data with
established gene pathways. Fisher’s exact test was used to
quantify the degree of association with these pathways.
When the cells with the risk haplotype (both stimulated
and unstimulated) were compared to those with the non-
risk haplotypes, three canonical pathways were found with
statistically signiﬁcant (P<0.01) association: the interferon
(Figure 1), Toll-like receptor (Figure 2), and B-cell receptor
(Figure 3) pathways. Interestingly, all three of these pathways
havesigniﬁcantimplicationsforlupus.Thesethreecanonical
pathways and relative changes in expression following EBV
exposure are represented in Figures 1–3 and Table 3.
3.3. Identiﬁcation of Individual Genes Diﬀerentially Expressed
by IRF5 Haplotype. Several genes in the interferon pathway
exhibited diﬀerential expression between either the risk and
protective haplotypes or the EBV exposed and unexposed
conditions. Genes with diﬀerential expression were selected
basedoninclusioninasigniﬁcantlyassociatedpathway,aver-
age expression values of at least thirty for one condition, and
diﬀerentialexpressionofatleast1.5-fold.Diﬀerentialexpres-
sion comparisons were done both with the unstimulated
and the EBV-infected states (Table 3). Several genes were
diﬀerentially expressed in the interferon pathway, including
interferon-induced transmembrane protein 1 (IFITIM1),
signal transducer and activator of transcription 1 (STAT1),
IFNα receptor 2 (IFNAR2), 2 –5 -oligoadenylate synthetase
1( OAS1), and MX1. The expression patterns of these genes
varied based on IRF5 haplotype and EBV infection status
(Figure 1).
IFITM1 was more strongly expressed in the risk cells
than in the nonrisk in the unstimulated condition (2.1-
fold diﬀerence). When the cells were exposed to EBV, this
diﬀerence disappeared, a result of a greater increase in
expression (4.8-fold) in the nonrisk cells than the risk (2.8-
fold). STAT1 was slightly underexpressed in the risk cells
than in the nonrisk prior to EBV exposure (1.3-fold), but
after EBV exposure it was more highly expressed in the risk
cells (1.3-fold). IFNAR2 acted in the opposite manner; its
expression was higher in the risk cells in the unstimulated
condition(1.7-fold),buthigherinthenonriskcellsafterEBV
infection (1.3-fold). IFNAR2 is an interferon receptor that
contributesdirectlytotheresponsetointerferon,makingthis4 Journal of Biomedicine and Biotechnology
Table 1: Frequency of IRF5 haplotypes in lupus patients and healthy controls. Haplotype frequencies observed in controls and systemic
lupus erythematosus (SLE) patient cohort at single-nucleotide polymorphisms rs2004640 (T :r i s k ,G: protective) and rs10954213 (A: risk,
G: protective).
Haplotype Allele 1 Allele 2
Frequency
(patients)
n = 1390
Frequency
(controls)
n = 2039
SLE risk
1 TA TA 0.2576 0.1947 Risk/risk
2 TA TG 0.4460 <0.0001 Risk/neutral
3 GA GG 0.2108 0.2737 Protective/protective
4 GG TG 0.0165 0.1810 Protective/neutral
Table 2: Eﬀect of the IRF5 risk haplotype on the expression of gene sets. Gene set enrichment analysis showed gene sets enriched in the
risk haplotypes of either SLE-unaﬀected controls or SLE patients without EBV infection. Genes shown have a false discovery rate (FDR) of
<25%.
Gene set name Aﬀected pathways or cellular
conditions
No. of
genes
Normalized
enrichment
score
P value FDR
q-value
Unaﬀected controls
CROONQUIST IL6 STROMA UP IL-6 exposure 37 −2.026 0.0018 0.038
PASSERINI INFLAMMATION Inﬂammation 23 −1.751 0.0112 0.212
PASSERINI PROLIFERATION Proliferation 62 −1.782 <0.0001 0.224
ADIP DIFF CLUSTER2 Diﬀerentiation 41 −1.752 0.004 0.225
CROONQUIST RAS STROMA DN Ras activation 21 −1.757 0.0038 0.229
UVB NHEK3 C6 UV light exposure 27 −1.763 0.0039 0.234
HOHENKIRK MONOCYTE DEND DN Dendritic cell maturation 121 −1.724 0.0348 0.239
LEE DENA UP Murine liver cancer 59 −1.769 <0.0001 0.241
ZUCCHI EPITHELIAL DN Breast cancer metastasis 44 −1.785 0.0117 0.245
SLE patients
IFNALPHA HCC UP IFNα 29 −1.968 0.0038 0.042
IFNALPHA NL HCC UP IFNα 18 −1.878 0.0096 0.063
RADAEVA IFNA UP IFNα 49 −1.897 0.0059 0.07
IFNALPHA NL UP IFNα 27 −1.847 0.0099 0.075
BENNETT SLE UP SLE 28 −1.785 0.0082 0.138
gene very interesting in the context of interferon regulation
and responsiveness. OAS1 was overexpressed in the risk cells
compared to the nonrisk cells in both the unstimulated and
EBV-exposedconditions(1.5-foldand2.2-fold,resp.),aswas
MX1 (1.6- and 1.8-fold).
The TLR pathway also contained several genes that
were diﬀerentially expressed between the risk and protec-
tive haplotype-containing cells (Figure 2). Fos and myeloid
diﬀerentiation primary response gene 88 (MyD88)a r eb o t h
under expressed in the unstimulated risk cells compared to
the nonrisk (2.2- and 1.8-fold, resp.). Both of these genes
switch from being downregulated in the risk cells before
EBV exposure to upregulated in the risk cells after EBV
exposure (1.3- and 1.2-fold, resp.). Another very interesting
gene that was diﬀerentially expressed in the TLR pathway is
tumor necrosis factor α-induced protein 3 (TNFAIP3). It is
under expressed by 1.3-fold in the risk cells in the resting
condition. After EBV exposure, expression is even more
unbalanced, with 1.9-fold under expression in the risk cells.
Genes of interest that are overexpressed in the risk cells in
the TLR pathway without EBV exposure include CD14 (3.2-
fold), lymphocyte antigen 96 (LY96, or MD-2) (2.3-fold),
and TLR1 (1.7-fold).
The B-cell receptor (BCR) pathway exhibited diﬀerences
in gene expression due to the IRF5 risk haplotype (Figure 3).
CD79A and CD79B, which together form part of the
BCR, were both downregulated 2.2-fold in the uninfected
risk cells, but this diﬀerence disappeared after EBV infection.
Ras-related C3 botulinum toxin substrate 1 (RAC1), a gene
involvedinlymphocytediﬀerentiationandsurvival[49],was
overexpressed in risk cells under all conditions (1.5-fold in
mock infected cells, 1.7-fold in EBV infected cells). Expres-
sion of the signaling protein AKT1 and the transcription
factor NFκB2 were downregulated in EBV infected cells with
the IRF5 risk haplotype (1.9- and 3.4-fold, resp.). In three
othergenes,phosphatidylinositol 3kinasecatalyticsubunit α
(PIK3CA), nuclear factor of activated T cells 5 (NFAT5), and
glycogensynthase kinase 3β (GSK3B),the risk haplotype hadJournal of Biomedicine and Biotechnology 5
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Figure 1: Association of the canonical interferon pathway with the IRF5 haplotype. Na¨ ıve B cells were either exposed to EBV for 16 hours or
left unstimulated. Whole-genome expression levels were compared between cells with the risk and protective haplotypes using the Illumina
platform. Signiﬁcant association of the data set with the canonical IFN pathway was discovered using Ingenuity Pathway Analysis (P<
0.01). Interactions between genes in the interferon pathway based on Ingenuity Pathway Analysis are shown for both the unstimulated (a)
and the EBV-infected conditions (b). Blue gene symbols represent genes with relatively lower expression in the cells with the risk haplotype,
while genes with red shading are upregulated in the risk cells. IFIT3: IFN-induced protein with tetratricopeptide repeats 3, SOCS: suppressor
of cytokine signaling.
a 1.5- to 1.8-fold increase in expression. However, when EBV
was present, the risk haplotype showed a decrease of 1.6- to
1.9-fold of the same genes.
3.4. The Interferon Response Signature in Patients Depends
on Haplotype. Lupus patients have a heightened interferon
response signature in the peripheral blood [50–52]. This
signature is heritable and is associated with the IRF5 risk
haplotype [19, 26]. When we examined genes included in
the interferon response signature, we found an interesting
association with the IRF5 risk haplotype. Cells from the
SLE patients with the risk haplotype had an interferon
response signature under all conditions, whether exposed to
EBV or not. However, the cells from SLE patients with the
protective haplotype did not exhibit an interferon signature
without EBV infection. The diﬀerence in expression of
the interferon response genes between the unstimulated
patient risk and the unstimulated patient protective cells
was statistically signiﬁcant (P = 0.011) (Figure 4). The risk
haplotype cells derived from control individuals did not have
heightened baseline expression of interferon response genes.
After exposure to EBV, these cells developed an interferon
response signature that was similar to that seen in the
baseline and EBV-infected risk-haplotype lupus patients.
Interestingly, the patients with the protective haplotype did
not develop a strong interferon response signature even
after exposure to EBV, indicating that the IRF5 protective
haplotypeisdampeningtheresponsetointerferoncompared
to the risk haplotype (Figure 4).
4. Discussion
The IRF5 gene has been associated with risk for lupus. These
ﬁndings demonstrate that the lupus-associated polymor-
phisms in the IRF5 gene have wide-reaching eﬀects on B-cell
responses to infection. The gene sets that were enriched in
the risk haplotypes included interferon-related sets, which is
encouraging considering that the genotype being examined
is IRF5. Multiple gene sets that are related to lupus were
enriched in the cells with the risk haplotypes, including
IFNα sets, interleukin- (IL-) 6, inﬂammation, proliferation,
and monocyte and dendritic cell genes, in addition to the
SLE-related interferon gene set. The ﬁnding that these gene
sets are the most strongly enriched in the risk haplotype
indicates that the IRF5 risk haplotype has a strong inﬂuence
on interferon signaling and inﬂammation, processes that are
at the core of SLE. The ﬁnding that the most enriched gene
sets were associated with interferon and lupus also indicates6 Journal of Biomedicine and Biotechnology
Table 3: Genes exhibiting diﬀerential expression between risk and nonrisk cells in the canonical pathways identiﬁed through ingenuity
pathway analysis. Fold up/down column is positive in the case that the gene expression is higher in the risk haplotype cells, and negative
in the case that gene expression is higher in the nonrisk cells. PIK3CA: phosphoinositide-3-kinase, catalytic, alpha; RAC1: Ras-related C3
botulinum toxin substrate 1. ∗The IFNB1 gene is found in both the interferon and Toll-like receptor pathways.
Gene
pathway Gene
symbol
Mock infected 16 hours EBV live virus infected 16 hours
Avg.
nonrisk Avg. risk Ratio Fold
up/down
Avg.
nonrisk Avg. risk Ratio Fold
up/down
Interferon
IFNB1∗ 104.95 3.89 0.04 −26.99 5.39 9.15 1.70 1.70
STAT1 71.08 52.84 0.74 −1.35 184.29 244.12 1.32 1.32
OAS1 56.04 84.55 1.51 1.51 49.87 107.78 2.16 2.16
MX1 3179.14 5161.02 1.62 1.62 3409.35 6199.20 1.82 1.82
IFNAR2 959.14 1637.11 1.71 1.71 1437.47 1094.97 0.76 −1.31
IFITM1 439.88 944.41 2.15 2.15 2128.61 2602.68 1.22 1.22
Toll-like
receptor
IFNB1∗ 104.95 3.89 0.04 −26.99 5.39 9.15 1.70 1.70
FOS 116.48 53.84 0.46 −2.16 90.05 120.60 1.34 1.34
MYD88 281.53 152.57 0.54 −1.85 181.06 226.62 1.25 1.25
TNFAIP3 439.96 321.29 0.73 −1.37 728.35 377.23 0.52 −1.93
TLR1 26.50 46.76 1.76 1.76 67.59 116.37 1.72 1.72
LY96
(MD-2) 560.79 1274.32 2.27 2.27 1128.47 1208.54 1.07 1.07
CD14 401.17 1272.53 3.17 3.17 139.53 450.09 3.23 3.23
B-Cell
receptor
CD79B 2222.90 991.48 0.45 −2.24 797.14 827.44 1.04 1.04
CD79A 41.32 19.08 0.46 −2.17 6526.62 5973.72 0.92 −1.09
RAC1 1407.29 930.84 0.66 −1.51 4.36 2.64 0.61 −1.65
MAPK9 105.87 71.02 0.67 −1.49 62.50 80.35 1.29 1.29
AKT1 512.79 353.65 0.69 −1.45 13.02 6.74 0.52 −1.93
NFKB2 6.44 4.85 0.75 −1.33 495.75 147.18 0.30 −3.37
PIK3CA 25.86 40.05 1.55 1.55 79.96 49.71 0.62 −1.61
NFAT5 123.74 222.63 1.80 1.80 5.14 2.70 0.52 −1.91
GSK3B 68.58 123.65 1.80 1.80 177.23 91.07 0.51 −1.95
that these results are unlikely to be false positives obtained
by chance, since the variable being studied is an interferon-
aﬀecting gene.
The gene set enrichment analysis techniques that were
used are valuable because they identify not only individual
genes, but also how strongly pathways that include those
genes and the interactions between them are aﬀected by the
experimental conditions. This allows a much broader look
into gene networks than looking only at individual genes.
These studies point to the IRF5 risk haplotype having a
wide inﬂuence on interferon and inﬂammation. The results
identify targets for future investigation into the function of
the IRF5 polymorphisms as well as other genetic inﬂuences
on lupus.
As was the case with the gene set enrichment analysis,
the identiﬁcation of the interferon and Toll-like receptor
pathways through Illumina pathway analysis suggests that
the results are robust, as these are pathways that would be
expected to be modulated by the underlying IRF5 haplotype
of the donor. Interferon alpha is an extremely important
cytokine in lupus [53]. These studies suggest that the
interferon alpha pathway is strongly aﬀected by genetic
v a r i a t i o ni nt h eIRF5 gene, and show multiple genes that
could potentially be targets for understanding interferon in
lupus or potential therapeutic targets. Toll-like receptors are
involved in response to infection through the recognition of
pathogen-associated molecular patterns. Additionally, Toll-
like receptors are important in the pathogenesis of lupus.
They are capable of recognizing endogenous nucleic acids
in the context of immune complexes found in lupus patient
sera, thereby stimulating dendritic cell maturation and
interferon alpha production [25, 54–60] ,ap r o c e s sw h i c h
also involves IRF5 itself [25]. IRF5 is a very interesting tran-
scriptional regulator in that it acts as both an activator when
homodimerizedandblocksactivationwhenheterodimerized
with IRF7 [61, 62]. This mechanism of action may help
to explain how some of these pathways can exhibit relative
upregulation or downregulation depending on the other
conditions in the cell.
One of the more unexpected ﬁndings of this study
was the modulation of the B-cell receptor pathway by the
IRF5 haplotype. The B-cell receptor is important in the
recognition of antigen and the survival, maturation, and
proliferation of B cells. B cells produce the autoantibodiesJournal of Biomedicine and Biotechnology 7
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Figure 2: Association of the canonical Toll-like receptor pathway with IRF5 haplotype. Diﬀerential regulation of the TLR pathway was
seen using Ingenuity analysis (P<0.01). Unstimulated conditions are shown on the left, and EBV-exposed conditions on the right.
Genes with altered expression based on haplotype are shown as either red or blue. IKB: inhibitor of NFκB, IKK: IKB kinase, JNK: c-Jun
N-terminal kinase, LBP: lipopolysaccharide-binding protein, MKK: mitogen activated protein kinase kinase, NIK: NFκB inducing kinase,
PPARα: peroxisome proliferator-activated receptor α, TAB1: transforming growth factor β-activated kinase 1, TIRAP: Toll/IL-1 receptor
domain containing adaptor protein, and TRAF6: tumor necrosis factor receptor-associated factor 6.
involved in lupus, as well as being important for antigen
processing and presentation and T-cell activation. Diﬀer-
ences in the activation threshold or other eﬀects that may
be seen with altered B-cell receptor gene expression may be
very important to breaking self-tolerance or other aspects
of B cell biology involved in SLE. Of particular interest in
this respect is the recent ﬁnding that IRF5 controls antibody
class switching to IgG2A, allowing lupus-like autoimmunity
in mice [63]. The B-cell receptor and Toll-like receptor
pathways are involved in antibody class switching, and the
genes that were modulated by IRF5 variation in this study
could represent mechanisms through which the IRF5 risk
haplotype may contribute to class switching or other similar
variations in humans.
The interferon response signature has been identiﬁed as
a common feature in lupus. These studies examined how
polymorphisms in the IRF5 gene aﬀected the interferon
response signature in both patients and controls. Interest-
ingly, SLE patients with the risk haplotype demonstrated
an interferon signature in both the infected and uninfected
cells, while a strong interferon response was not found in the
patients without the risk haplotype even when stimulated by
EBV exposure. The controls with the risk haplotype lacked
the interferon response signature in the basal state, but
developed it after exposure to EBV, as would be expected.
TheseﬁndingssuggestthattheIRF5riskhaplotypeisintegral
for the interferon response signature in both patients and
controls. They also indicate that other factors contribute to
a basal interferon response in lupus patients, since the IRF5
risk haplotype was not suﬃcient for the response signature
to be present in the unstimulated control cells, as it was in
the patients with the risk haplotype.
Cells were infected with EBV for two reasons. The ﬁrst
was to identify diﬀerences in gene expression patterns when8 Journal of Biomedicine and Biotechnology
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Figure 3: Association of the canonical B-cell receptor pathway with IRF5 haplotype. BCR pathway genes demonstrate a signiﬁcant
enrichment of changes in expression levels based on IRF5 haplytype, as determined by Ingenuity analysis (P<0.01). The unstimulated
condition is shown on the left, and the EBV-exposed condition is shown on the right. Genes with altered expression based on haplotype are
shown as either blue or red. BLNK: B cell linker, CAM: Calmodulin, CN: Calcineurin, ERK: extracellular signal-regulated kinase, FCGR2B:
fragmentcrystallizableγ receptor2B,INPP5D:inositolpolyphosphate-5-phosphataseD(SHIP),MALT1:mucosaassociatedlymphoidtissue
lymphoma translocation gene 1, and PKC: protein kinase C.
cells were stimulated with a biologically relevant trigger for
interferon production. The second reason was to identify
areas that may start to explain the diﬀerences in EBV infec-
tion and response in lupus. Gene expression was examined
for genes in the three pathways found to be signiﬁcant
by ingenuity analysis. In several cases, (IFITM1, IFNAR2,
LY96, PIK3CA, NFAT5, and GSK3B) the baseline level of
gene expression was higher in the risk cells, but after EBV
infection,thegeneexpressionwascomparativelyincreasedin
theprotectivecells.Inothergenes,includingCD79A,CD79B,
STAT1,MyD88,andFos,expressionwaslowerintheriskcells
butthediﬀerencediminishedorreversedafterEBVinfection.
Expression of one gene, TNFAIP3, was lower in the risk than
in the protective haplotype subject unstimulated cells and
was comparatively diminished further after EBV infection.
These diﬀerences suggest several areas of investigation to
understand diﬀerences in B cell biology in lupus and show
that the IRF5 haplotype aﬀects multiple genes related to EBV
infection and response.
Although a detailed analysis of each gene involved in
these pathways is beyond the scope of this paper, the genes
with expression diﬀerences between the risk and protective
haplotypes are suggestive in several instances. One of the
genes identiﬁed with promise to aﬀect lupus is TNFAIP3.
This gene is a transcription factor that is produced in
response to inﬂammation. It has been shown to be critical
to limiting inﬂammation by terminating NFκB responses
[64].Variants have recently been associated with risk for
lupus and other autoimmune and inﬂammatory diseases
[65–71], and it is often suppressed in tumors, especially
lymphomas [66, 72, 73]. Other promising genes identiﬁed
by these experiments include STAT4, IFITM1,a n dIFNAR2,Journal of Biomedicine and Biotechnology 9
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Figure 4: Dependence of the interferon response signature on IRF5 haplotype in SLE patients. Interferon signature genes identiﬁed
in gene set enrichment analysis were compared between patients and controls, and between lupus patients with the IRF5 risk and
nonrisk haplotypes. Each column represents expression of genes of interest in individual subjects. (a) Interferon signature genes of
3 IRF5 nonrisk and 2 IRF5 risk SLE patients. Gene expression comparisons are between IRF5 risk and nonrisk SLE patients, either
nonstimulated or EBV infected. (b) Gene set enrichment of 3 control IRF5 risk haplotype individuals and 3 SLE patient IRF5 risk
haplotype individuals. Gene expression comparisons between IRF5 risk patients and controls from nonstimulated and EBV-infected B cells.
ADAR: adenosine deaminase, BAK: Bcl2-antagonist/killer, BTG: B cell translocation gene, C1S: complement component 1S, CASP: caspase,
CEBPD: CCAAT/enhancer-binding protein δ, eIF2B: eukaryotic translation initiation factor 2B, FOSL: Fos-related antigen, HADHB:
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase β subunit, HLA: human leukocyte
antigen,PHLDA:pleckstrinhomology-likedomainfamilyA,PMAIP1:phorbol-12-myristate-13-acetate-inducedprotein1(Noxa),PRAME:
melanoma antigen preferentially expressed in tumors, RBBP: retinoblastoma binding protein, SF3A: splicing factor 3A, TRIM: tripartite
motif, VAT: vesicle amine transport, and XRCC: X-ray repair cross-complementing (Ku70).
which are all involved in the response to interferon, and
several B cell signaling genes, including NFAT5, GSK3B,a n d
NFκB2.
Although EBV was used in part to simulate an infected
state in B cells, EBV itself could be involved in the etiology
of lupus by aﬀecting several pathways. The three pathways
identiﬁed here are all involved in EBV infection. EBV
may stimulate these pathways through several mechanisms,
including both infection and binding of virions to the
receptors involved in these pathways. Although the eﬀect of
EBV infection on diﬀerential gene expression was somewhat
variable, for many of the genes examined in this study there
was overexpression in the risk cells, which subsequently
diminished after EBV infection. This pattern, as well as that
seen with the interferon response signature, suggests that the
IRF5 risk haplotype makes these cells appear more activated
in the resting state. Because of this heightened activation
state, there is less diﬀerence in the response to EBV infection
in the risk cells, with the nonrisk cells often catching up
to or passing the risk cells in expression of several genes
following viral infection. An activated basal state would
be likely to promote inappropriate cellular responses and
possibly heightened sensitivity to self-antigens, including
those recognized by TLRs.
These ﬁndings identify several key pathways that are
aﬀected by the IRF5 risk haplotype and are involved in the
B cell response to antigen stimulation and viral infection.
Many of the genes involved in these pathways have deﬁnite
potential to alter the response to EBV infection and aﬀect
the development of lupus. These merit further investigation.
Since all of these pathways are likely to be involved in the
development of lupus, further comparison of these pathways
in other cell types such as plasmacytoid dendritic cells will
be beneﬁcial to understanding the origins and pathogenesis
of lupus. It will also be beneﬁcial to examine more closely the
role of EBV in regulating expression of these genes, through
the use of EBV mutants, and to dissect the role of IRF5 in
each pathway and gene set identiﬁed.10 Journal of Biomedicine and Biotechnology
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